Trevi Therapeutics Prices $150M Offering
Analysis based on 11 articles · First reported Apr 16, 2026 · Last updated Apr 17, 2026
The public offering by Trevi Therapeutics is expected to provide significant capital, which could positively impact its stock price and ability to fund ongoing clinical trials for Haduvio. The involvement of major financial institutions like Morgan Stanley as underwriters lends credibility to the offering.
Trevi Therapeutics, a clinical-stage biopharmaceutical company, announced the pricing of its underwritten public offering of 11,600,000 shares of common stock at $13.00 per share, aiming to raise approximately $150 million. The offering is expected to close around April 20, 2026. Trevi Therapeutics also granted the underwriters, including Morgan Stanley, Leerink Partners, Cantor Fitzgerald, Stifel, and Oppenheimer Holdings, a 30-day option to purchase up to an additional 1,740,000 shares. The proceeds will support the development of Haduvio, an investigational therapy for chronic cough.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard